The global cell therapy raw materials market is valued at approximately $5.43 billion in 2024 and is expected to grow to $6.75 billion by 2025. By 2034, the market is projected to reach nearly $48.54 billion, reflecting a significant annual growth rate of 24.5% from 2025 to 2034. The increase in demand for cell therapies, particularly in treating conditions like cancer, rare diseases, and genetic disorders, is a key driver of this market’s growth.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5399
Cell therapy raw materials refer to substances used in the manufacturing of cell, tissue-engineered, or gene therapies, which are not part of the final product. These include components such as cell isolation reagents, culture media, cryopreservation solutions, and disposables like plasticware and bioprocessing bags. The choice of raw materials plays a crucial role in ensuring the safety and effectiveness of the final therapy. By selecting the right materials early from trusted suppliers, manufacturers can streamline production, reduce costs, and improve the chances of regulatory approval.
The rapid advancement of cell and gene therapy is evident in the growing number of clinical trials and approved treatments. As the field expands, so does the focus on optimizing the materials and manufacturing processes involved in creating these therapies.
In September 2024, Dana Cipriano, Vice President of Analytical Services at SK Pharmteco, highlighted the importance of maintaining a secure and reliable supply chain in the rapidly growing cell and gene therapy sectors. Cipriano emphasized their partnership with Cryoport, which underscores their commitment to providing high-quality services tailored to meet both client and patient needs.
In November 2024, QPS Holdings, LLC opened a new Cell Therapy business unit at their Springfield site in Missouri. This new facility includes a Leukopak collection and blood product processing center, designed to address the rising demand for blood products in cell and gene therapy.
In March 2024, ACROBiosystems launched a new initiative to support the development of advanced cell and gene therapies and ex vivo cell production. This new venture aims to assist manufacturers with cutting-edge solutions for cell-based treatments.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/cell-therapy-raw-materials-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5399
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The U.S. AI in healthcare market, valued at USD 11.57 billion in 2025, is projected to expand to USD 194.88… Read More
The global next-generation AI in life sciences market is witnessing rapid expansion, projected to reach several hundred million USD by… Read More
The U.S. oncology pharmaceutical market is poised for substantial growth, projected to generate hundreds of millions in revenue from 2025… Read More
The global autologous cell therapy market—valued at US$ 9.6 billion in 2024 and US$ 11.41 billion in 2025—is projected to… Read More
The U.S. biotechnology market is on a high-velocity growth path — from USD 699.02 billion in 2025 to USD 2,004.86… Read More
AI in Healthcare Market is projected to grow from USD 37.98 billion in 2025 to USD 674.19 billion by 2034… Read More